Q-omics provides the consensus-scored RPL37P10 profile across patient tissues and cancer cell-line models. RPL37P10 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL37P10 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, RPL37P10 RNA expression shows 4,294 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight BLCA, STAD, and OV as cancer lineages where RPL37P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL37P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL37P10 survival associations across molecular data types. RPL37P10 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL37P10 RNA expression–survival associations across cancer types. High RPL37P10 expression shows unfavorable associations in SKCM, LIHC, PAAD, THYM and MESO, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL37P10 RNA expression.
This table summarizes RPL37P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL37P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL37P10 shows higher tumor expression in STAD and KIRC. The STAD box plot shows higher RPL37P10 RNA expression in tumor versus normal tissue (log2 FC = +0.314, t-test p = .004).
This table shows molecular features associated with RPL37P10 in patient tissues and cancer cell lines. In patient samples, RPL37P10 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
